Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Gross Margin (2017 - 2025)

Historic Gross Margin for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to 83.69%.

  • Aclaris Therapeutics' Gross Margin fell 12600.0% to 83.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 85.62%, marking a year-over-year decrease of 40000.0%. This contributed to the annual value of 85.09% for FY2024, which is 39600.0% down from last year.
  • As of Q3 2025, Aclaris Therapeutics' Gross Margin stood at 83.69%, which was down 12600.0% from 71.02% recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Gross Margin registered a high of 95.87% during Q4 2023, and its lowest value of 20.51% during Q1 2022.
  • Moreover, its 5-year median value for Gross Margin was 68.04% (2023), whereas its average is 62.88%.
  • The largest annual percentage gain for Aclaris Therapeutics' Gross Margin in the last 5 years was 652400bps (2022), contrasted with its biggest fall of -118500bps (2022).
  • Quarter analysis of 5 years shows Aclaris Therapeutics' Gross Margin stood at 23.45% in 2021, then skyrocketed by 278bps to 88.69% in 2022, then rose by 8bps to 95.87% in 2023, then dropped by -4bps to 92.35% in 2024, then fell by -9bps to 83.69% in 2025.
  • Its Gross Margin was 83.69% in Q3 2025, compared to 71.02% in Q2 2025 and 65.22% in Q1 2025.